Clostridioides Difficile Infection Clinical Trial
Official title:
ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Subjects With Recurrent Clostridioides Difficile Infection (RCDI)
Cohort 1: Subjects who had a Clostridioides difficile infection (CDI) recurrence in study SERES-012 within 8 weeks of receipt of study drug will be eligible. The purpose of this cohort is to assess safety and efficacy of SER-109 in reducing recurrence of CDI in adults who had a CDI recurrence within 8 weeks after receipt of SER-109 or Placebo in study SERES-012. Cohort 2: Cohort 2 is an open-label program for subjects who were not part of SERES-012. The purpose of this cohort is to describe safety and tolerability of SER-109 in subjects 18 years of age or older with at least a first recurrence of CDI.
Cohort 1 is an open-label extension of study SERES-012. Subjects who had a CDI recurrence in study SERES-012 within 8 weeks of receipt of study drug, have responded to a course of standard of care (SOC) antibiotic treatment, will receive an oral dose of SER-109. A treatment regimen of SER-109 is defined as an oral dose of SER-109 (4 capsules once daily) for 3 consecutive days. Approximately 30 eligible subjects with recurrent CDI disease from study SERES-012 are expected to enroll. Screening for this study will begin at the Recurrence Visit of Study SERES-012. Cohort 2 is an open-label program for subjects who were not part of SERES-012. Subjects 18 years of age or older who had one or more CDI recurrence and have responded to a course of antibiotic treatment will receive an oral dose of SER-109. The CDI recurrence must be confirmed by a positive C. difficile stool toxin or polymerase chain reaction (PCR) assay to confirm eligibility. A treatment regimen of SER-109 is defined as an oral dose of SER-109 (4 capsules once daily) for 3 consecutive days. Approximately 200 eligible subjects with recurrent CDI disease are expected to enroll. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03895593 -
Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
|
||
Completed |
NCT04675723 -
The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection
|
||
Withdrawn |
NCT04679324 -
The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infection
|
||
Recruiting |
NCT05693077 -
Clostridioides Difficile Colonisation
|
Phase 1 | |
Completed |
NCT04668014 -
The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile Infection
|
||
Recruiting |
NCT05709184 -
Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection
|
N/A | |
Terminated |
NCT05526807 -
Ursodeoxycholic Acid in C. Difficile Infection
|
N/A | |
Recruiting |
NCT06306014 -
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06237452 -
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
|
Phase 3 | |
Terminated |
NCT04802837 -
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
|
Phase 3 | |
Active, not recruiting |
NCT04885946 -
Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection
|
N/A | |
Recruiting |
NCT04305769 -
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
|
Phase 2 | |
Recruiting |
NCT06106698 -
Washed Microbiota Transplantation for Clostridioides Difficile Infection
|
||
Active, not recruiting |
NCT04781387 -
Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection
|
Phase 2 | |
Completed |
NCT03595553 -
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
|
Phase 3 | |
Completed |
NCT03595566 -
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
|
Phase 3 | |
Completed |
NCT04725123 -
Addressing Personalized Needs in Clostridioides Difficile Infection
|
N/A | |
Not yet recruiting |
NCT05852587 -
Xylitol Use for Decolonization of C. Difficile in Patients With IBD
|
Phase 1 | |
Completed |
NCT03788434 -
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
|
Phase 2 | |
Recruiting |
NCT05612672 -
Evaluation of GeoHAI Implementation
|
N/A |